PATENT CLAIM ANALYSIS

Application Number: 16044636
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["435", "007100"]

Abstract:
A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

Claim (Index 1):
An antibody comprising an antigen recognition domain which specifically binds amphiregulin and comprises:\n (i) complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 4, 6, 8, 18, 20 and 22 (AR30), wherein said CDRs set forth in SEQ ID NOs: 18, 20 and 22 are arranged in a sequential order from N to C on a light chain of the antibody and said CDRs set forth in SEQ ID NOs: 4, 6 and 8 are arranged in a sequential order from N to C on a heavy chain of said antibody; (ii) CDRs as set forth in SEQ ID NOs: 32, 34, 36, 48, 50 and 52 (AR558), wherein said CDRs set forth in SEQ ID NOs: 48, 50 and 52 are arranged in a sequential order from N to C on a light chain of the antibody and said CDRs set forth in SEQ ID NOs: 32, 34 and 36 are arranged in a sequential order from N to C on a heavy chain of said antibody; or (iii) CDRs as set forth in SEQ ID NOs: 64, 66, 68, 94, 95 and 96 (AR37), wherein said CDRs set forth in SEQ ID NOs: 94, 95 and 96 are arranged in a sequential order from N to C on a light chain of the antibody and said CDRs set forth in SEQ ID NOs: 64, 66 and 68 are arranged in a sequential order from N to C on a heavy chain of the antibody.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 95.0
- Lexical Diversity: 2.05714
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13641174', '13488270', '12464057', '14055222', '15508112']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5831799063838196
- 35 USC 102 Novelty (BERT): 0.5355797023697854
- Combined Prediction Score: 0.5784198859824161
- Mean Citation Score: 339.08681399999995
- Max Citation Score: 367.096
- Similarity Product: 262.2359192442894

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test